BAILII is celebrating 24 years of free online access to the law! Would you consider making a contribution?
No donation is too small. If every visitor before 31 December gives just £1, it will have a significant impact on BAILII's ability to continue providing free access to the law.
Thank you very much for your support!
 |
[Home] [Databases] [World Law] [Multidatabase Search] [Help] [Feedback] | |
United Kingdom Intellectual Property Office Decisions |
||
|
You are here: BAILII >> Databases >> United Kingdom Intellectual Property Office Decisions >> Aeomica Inc. (Patent) [2005] UKIntelP o19705 (13 July 2005) URL: http://www.bailii.org/uk/cases/UKIntelP/2005/o19705.html Cite as: [2005] UKIntelP o19705 |
||
[New search] [Printable PDF version] [Help]
For the whole decision click here: o19705
Summary
The application relates to a human polypeptide, named RALGDS-like protein 3 (RGL3), which is a guanine nucleotide exchange factor for the small GTPase Ral and a downstream effector for both Rit and Ras, and is thought to be a regulator of cellular proliferation and transformation. Further claims relate to standard features or applications of polypeptides and polynucleotides which would be considered when any protein and/or gene is identified. Claims to the polypeptide and polynucleotide were held to lack inventiveness over the prior art disclosed in two documents. Both documents disclosed the RGL3 protein from the mouse and were used to infer a function for human RGL3 based on similarities within certain domains and in overall structural organization. Given the information contained in the cited documents, together with the common general knowledge of the skilled man, it was considered obvious to look for RGL3 orthologs in species other than the mouse and therefore the identification of the human RGL3 sequences did not involve any inventive step.
